US recession warning for pharma, study claims

The signs of an imminent US recession are real, according to a market consulting firm, and there is a danger that unprepared pharmaceutical or biotechnology firms will be even more at risk than the rest of the economy. More than other sectors, the drug industry faces increased pricing and regulatory pressures, at a time when there is a shortfall in the number of new products entering the market. By aggregating data from 36 drug companies, including the top 10 drug majors, Best Practices argues it can provide benchmarking metrics for executives to measure their own company's performance.

The report, available from the Best Practices web site (www.best-in-class.com), is titled: US Pharmaceutical Budget and Staffing Excellence: Benchmarking the Resources Required to Drive Productivity and Growth.